Manufacturer
ASTELLAS PHARMA EUROPE B.V.
Contents
Solifenacin succinate
Indication
Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency in patients w/ overactive bladder syndrome.
Instruction
May be taken with or without food: Swallow whole, do not chew/crush.
Drug interaction
Anticholinergic, cholinergic receptor agonists, simultaneous treatment of solifenacin & a potent CYP3A4 inhibitor is contraindicated in patients w/ severe renal impairment or moderate hepatic impairment. Other CYP3A4 substrates w/ higher affinity (eg, verapamil, diltiazem) & CYP3A4 inducers (eg, rifampicin, phenytoin, carbamazepine). Drugs which prolong the QT/QTc interval (erythromycin, quinidine, procainamide, disopyramide, sotalol, amiodarone, cisapride, fluconazole, amitriptyline, haloperidol, chlorpromazine, thioridazine, pimozide & droperidol).
Malaysia
